1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Bipolar Disorder (Manic Depression) Report is to understand the market and pipeline status of the drugs around the Bipolar Disorder (Manic Depression) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Bipolar Disorder (Manic Depression). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Bipolar Disorder (Manic Depression).
- A review of the marketed products under prescription for Bipolar Disorder (Manic Depression), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Bipolar Disorder (Manic Depression) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Bipolar Disorder (Manic Depression) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Bipolar Disorder (Manic Depression) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Bipolar Disorder (Manic Depression) drugs.
- Coverage of Bipolar Disorder (Manic Depression) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Bipolar Disorder (Manic Depression) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Bipolar Disorder (Manic Depression).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Bipolar Disorder (Manic Depression).
- API intelligence over marketed drugs forBipolar Disorder (Manic Depression)and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Bipolar Disorder (Manic Depression).
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Bipolar Disorder (Manic Depression)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Bipolar Disorder (Manic Depression)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Bipolar Disorder (Manic Depression)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Bipolar Disorder (Manic Depression) Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, US, (Year), 2017
- Bipolar Disorder (Manic Depression) Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Bipolar Disorder (Manic Depression) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, Europe by Country, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, India by State, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, China by Province, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers by Geography 2017
- Bipolar Disorder (Manic Depression) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Bipolar Disorder (Manic Depression), 2017
- Discontinued Drugs for Bipolar Disorder (Manic Depression), 2017


List of Figures

- Bipolar Disorder (Manic Depression) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, US, (Year), 2017
- Bipolar Disorder (Manic Depression) Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Bipolar Disorder (Manic Depression) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, Europe by Country, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, India by State, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers, China by Province, 2017
- Bipolar Disorder (Manic Depression) Drugs, API Manufacturers by Geography 2017
- Bipolar Disorder (Manic Depression) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Bipolar Disorder (Manic Depression) Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.